

AnteoTech Ltd

Managing Director AGM Presentation

BRISBANE, AUSTRALIA, 14 November 2023. AnteoTech Ltd (ASX:ADO) will today present the attached presentation at its Annual General Meeting. A copy of the Managing Director's presentation is attached.

This announcement has been authorised for release by Andrew Cook, Company Secretary.

Media and investor enquiries: Friederike Graser, on +61 7 3219 0085 or investors@anteotech.com

Company and Partnering enquiries: David Radford, CEO, on + 61 7 3219 0085

For further information, please check our website www.anteotech.com

About AnteoTech - AnteoTech Ltd (ASX:ADO)

AnteoTech is a revenue stage company that provides solutions for the clean energy and life sciences markets using our proprietary applied materials technology. In the rapidly growing clean energy market, our lead product Anteo X, has been proven to provide significant improvement in anode performance and the Company has partnered with global suppliers to the lithium-ion battery manufacturing industry, with first revenues targeted for late 2023. The portfolio includes a proprietary high silicon anode in late-stage development, made with unrefined silicon which offers advantages of size, weight and cost. The Life Sciences division services the Point-of-Care and In vitro diagnostics markets from global diagnostics companies to technology developers. The unique characteristics of AnteoBind™ provides strong advantages in bioconjugation to rapidly speed up testing procedures and improve accuracy.

AnteoTech - Social Media Policy

AnteoTech is committed to communicating with the investment community through all available channels. Whilst ASX remains the prime channel for market sensitive news, investors and other interested parties are encouraged to follow AnteoTech on Twitter ([@AnteoTech_](https://twitter.com/AnteoTech_)), LinkedIn. Subscribe to AnteoTech Latest News emails - visit our website at www.anteotech.com and subscribe to receive our email alert service.



2023 Annual General Meeting Managing Director's Presentation

LEADING THE CHARGE

14 November 2023

COMMERCIAL-IN-CONFIDENCE

This document is the property of AnteoTech Ltd and shall not be communicated to third parties and/or reproduced without prior written agreement. © AnteoTech Ltd 2023

COMMERCIALLY EXPERIENCED LEADERSHIP TEAM



David Radford
Managing Director

- Highly experienced senior executive with a track record of successful commercialisation
- Former CEO of Nanosonics, General Manager Asia of GE Clinical Systems Services



Katrina Byrne
Chief Operating Officer

- Extensive domestic and international multi-industry experience in operations, projects and supply chain management.
- Senior Executive positions leading rapid commercialisation of R&D, Boeing and Rio Tinto



Andrew Cook
Chief Financial Officer

- 20+ years' experience in senior financial roles — focus on energy & renewables
- Track record in leading international teams and negotiating contracts with large corporates including roles at Origin Energy and Energy Queensland



Friederike Graser
Director Strategic Growth Initiatives

- 12+ years' experience in emerging renewable technologies and energy sector
- Experience in merger and acquisitions, and capital raising programs



Tsui Min Lian
Chief Marketing Officer

- Experience managing healthcare businesses to grow to become profitable, efficient market leaders
- 17+ years' driving change and transformation with GE, ResMed and Toll Holdings



Manuel Wieser
Chief Technology Officer

- 11+ years' experience in Li-ion battery product development and technology commercialisation
- Track record in delivering global commercial partnerships and taking technology from lab-scale to pilot production

FY2023 ACHIEVEMENTS — BUILDING THE FOUNDATIONS FOR GROWTH

Position AnteoTech for short and mid-term revenues in Clean Energy and Life Sciences to create long term value

Commercial Leadership Team

Experienced leadership team focussed on commercial outcomes

Marketing-led sales driven team



Realigned Resources

Reduced cost base and realigned resources into Clean energy

Restructured for a market-led, sales-driven culture



Trinseo – MOU

MOU with global specialty materials solutions provider, Trinseo Europe, to provide for a clear path to a commercial agreement for Anteo X™



Expanded Capabilities

Strengthened the leadership team

- Tsui Min Lian – *Chief Marketing Officer*
- Andrew Cook – *Chief Financial Officer*



Capital + Investors

Strengthened balance sheet: \$4.7m

Placement & Share Purchase Plan

\$3.8m from R&D rebate

Attracted new institutional investors



Wyon – MOU

Signed MOU for development of silicon anode technology to improve their rechargeable miniature and micro batteries in MedTech



Facility Development

Work commenced on the construction of Anteo X production facility with targeted first production in early Q1-CY24



Anteo X Award Winning

- Renewable Energy category – Australian Climate Technology Awards
- Manufacturing Innovation Award Australian Technologies Competition



Growing Pipeline

Showcased Anteo X at The Battery Show Europe 2023 in Stuttgart

- Generated >100 sales leads
- Identified 12 key target relationships



REFOCUSSED PRIORITIES – INVESTING FOR HIGH RETURNS

Significant refocus into CET and roles that build value into the business



Realignment of Company Resources

- **25% reduction** in headcount
- **52% reduction** Life Science resources
- **Ceased** point-of-care initiatives
- No expensive clinical studies or regulatory submissions



Expanding Expertise and Resources for CET

- **75% increase** in Clean Energy team
- Recruited additional **industry expertise**
- **Reallocation of resources** from Life Sciences to Clean Energy



Driving Short-to-mid Term Revenues

- All programs focused upon **short-term revenue growth**
- Strategic partnerships focused on **delivering revenue** in FY24

ANTEOTECH PRODUCTS – INNOVATION DEFINING THE FUTURE

Proven technologies for the rapidly growing battery anode and life science diagnostics markets



Clean Energy Technology


Anteo X™

Anteo X is a **performance enhancing additive** that reinforces battery binders in silicon containing anodes and **improves their performance** in next-gen lithium-ion batteries



High Silicon Anode


AnteoTech's **High Silicon Anode** utilises products, formulations and processes to develop a **proprietary anode** which the Company will **license to future partners**



Life Sciences

AnteoBind™

AnteoBind is a unique **product** that offers significant productivity gains in the manufacture of diagnostic products



Development Services

FOCUS & EXECUTION THE KEY TO DRIVE REVENUES

Strategies to drive revenues in 2024 — focused on partnering and sales generation with appropriate supporting infrastructure

1

Clean Energy commercialisation and development activities

Sales and marketing to deliver **early commercial revenues** and **partnerships** for Anteo X and anode development programs

2

Anteo X™ production facility to meet expected demand

Complete construction and commission our production facility to 20,000 litre annual capacity and beyond

3

Optimisation & development of High Silicon Anodes

Internal development and customer partnerships driving next generation battery technologies

4

Commercial activities in Life Sciences focused on revenues


Targeted sales and marketing activities with large Life Science and vaccine manufacturing companies

CLEAN ENERGY TECHNOLOGY

Enabling the transition to next
generation batteries

EARLIER DEVELOPMENT WORK DRIVES LONG-TERM UPTAKE OF ANTEO X™

Early-stage development agreements drive Anteo X annuity sales across the anode development value chain



LEADING THE CHARGE: LEARNINGS FROM EUROPE

Our European counterparties are “marquee brands” and market leaders within their own segments, and acknowledge AnteoTech as a credible business partner



Key Takeaways - European Customer Meetings

- Anode **technology and development is lagging**
- **↑silicon is a core challenge** – 8% to 10% normal
- **Integration is a problem** – lack of expertise
- **Data is critical** – many technologies don’t deliver
- **Partnering** is critical to accelerate development
- Customers willing to **pay for access and expertise**
- Many startups promise but don’t deliver – **credibility is key**



AnteoTech’s Value Proposition

- Demonstrated ability to make the **transition to higher silicon** content (>20%) and **drive performance improvements**
- Anteo X™ is enabling the **cost-effective** development of High Silicon Anodes
- Significantly greater focus upon anodes than most EV companies – **expertise and know-how**
- **Portfolio of results** with data to substantiate claims
- **High credibility**

TARGETED REVENUE OPPORTUNITIES IN THE ANODE VALUE CHAIN

AnteoTech solutions span the anode development process. Estimated sales opportunities >AUD\$1b



PRODUCTION FACILITY TO SUPPORT COMMERCIAL ORDERS

Construction has commenced to support commercial initiatives – Anteo X™ and battery design and testing capabilities

First production facility

- Brisbane-based **20,000L production facility** is under construction with commissioning targeted for **early Q1-CY24**
- Initial **cost of \$0.7m – nominal incremental cost** to move to 40,000L and then 80,000L annual capacity

Anteo X production – Controlling initial product and quality

- **Simple chemical production** process with minimal labour requirement
- Builds credibility and supports **sales initiatives**
- Targeting **material gross margins**

Battery testing capability

- Expansion from 450 batteries on test to **1,000 parallel testing channels**



Above: Expansion to battery testing laboratory in progress

LIFE SCIENCES

Building new revenue opportunities with AnteoBind™


NEW MARKETING APPROACH TO DRIVE GROWTH

Enhanced formulation of AnteoBind™, a targeted sales and marketing approach coupled with a new pricing



Validated AnteoBind Features

- AnteoBind **is easier to use** vs. conventional chemistry
- Stability of particles for >12months once activated enables **batch reproducibility, reduced wastage** and **processing time**
- **Reduction in antibodies** and **labour costs** are key differentials
- Safe, non-hazardous **achieving highest possible ESG standards**
- **New market for pre-activated particles** estimated ~ >\$500M AUD



AnteoTech's Value Proposition

- **Expansive research and knowledge** of particle activation
- AnteoBind enables the **creation of a new “particle market”** with pre-activated particles
- **Reformulation** capability decreasing price
- Significant **reductions in antibody usage** (>30%) and labour(40%)
- **Effective across a range of particles** – lateral flow, enzyme-linked immunoassay and chemiluminescence

COMMERCIALISATION PROGRESS UPDATE FOR CY2024

Leveraging AnteoTech's know-how and key AnteoBind™ benefits to create opportunities for near and mid-term revenues

AnteoBind Go-to-Market Strategy



AnteoBind

Reformulation



Pricing

Pricing alignment
for new target
markets



Target Marketing

Pre-activated particle
market
AnteoBind Sales/
activation services



Growth

Negotiations currently
underway include:

- Particle manufacturer
- Vaccine manufacturer

DIVERSIFIED SALES MODEL TO MAXIMISE CAPTURE OF TARGET MARKETS

Near-term revenue streams from Proprietary AnteoBind™ Sales and Contract Assay Development Services



Growing commercial footprint & revenue base



LOOKING FORWARD — COMMERCIAL MILESTONES*

2023

- **Capital Raise** – funds growth + new institutions ✓
- Trinseo and Wyon **Anteo X™ technology validation** ✓
- Construction commences on **Anteo X production facility** ✓
- Anteo X **first commercial revenues** – EV company ✓
- **Commercial agreement** – Trinseo ◐
- **Commercial agreement** for **AnteoBind™** ◐
- **Commercial agreement** – Battery Manufacturer ◐

2024 & Beyond

2024

- Anteo X **production commencement**
- **Development agreements** – EV companies
- **Additional** Clean Energy **partnerships**
- **Commercial agreement** – Wyon
- **Commercial agreements** for **AnteoBind**
- Anteo X **production facility scale up**
- **Development partnerships** – anode optimisation

2025

- **First commercial revenues** – High Silicon Anode

*All milestones are estimates and actual timing and events may vary

FUNDING OUR PATHWAY

Reduced costs and refocused resources to higher value opportunities in the clean energy market

Market Cap¹

\$57.1m

Cash + R&D Rebate²

\$7.7m

Debt

Nil

Lower FY24 Cost base³ anticipated
~\$3m *vs. FY23*

FY24 Y-o-Y Revenue Growth anticipated
100%

R&D Rebate 2023
\$3.8m

Shares on issue	2,196 million
Options	142 million
Board & Management	1.4% + Incentive Options
Institutions	~5%
Retail	9,880 shareholders

¹ Closing share price on 10 November 2023

² ASX Quarterly for September 2023 quarter and \$3.77m R&D rebate received 12 October 2023

³ Excluding Depreciation, Amortisation, Share-based Payments and one-off costs

ENVIRONMENTALLY & SOCIALLY RESPONSIBLE


AnteoTech is committed to being a low carbon footprint, sustainable company with the highest possible ESG standards



Quality & Accreditations


Hold ISO 13485 and ISO 9001 accreditations

Production in tier 1 jurisdiction with low sovereign risk and a robust regulatory framework



Advancing Clean Energy Battery Technology

AnteoTech products improve performance of battery technologies, using fewer mined resources, and easy-to-use technologies that do not require high heat or solvents for activation



Eco-Friendly Production and Low Carbon Footprint

Unrefined silicon with lower processing requirement compared to competition

Significant contributor to decarbonisation of battery manufacturing processes



Diagnostics Enabling Life-Saving Medical Interventions

AnteoTech enables point-of-care diagnostics across a range of clinical applications bringing critical decision making to the point of care in medical cases



Cyber Security Protections

AnteoTech has migrated to outsourced model with high quality service vendor

Multi-layer security in place

Cyber security insurance in place



Diversity and Inclusion

Employer of choice

40% Female directors

50% Female executive leadership

>50% of the Company is female

17 Nationalities represented

FIVE KEY TAKEAWAYS



Next Generation Battery Technology

Patent-protected, market-leading, platform technology which unlocks the path to high silicon content battery anodes



Productivity Enhancing Technology

AnteoBind™ enables reduced input costs, antibody and labour costs




Partnering with Industry Leaders – Technology Validated

Multiple international organisations have validated Anteo X™ and AnteoBind



Multiple, Large Revenue Opportunities

Product sales and development revenue opportunities are near term
Large volume sales potential for Anteo X and AnteoBind



Building Blocks are in place to Succeed

Commercial leadership team in place with realignment of resources to drive growth